GenSci144 Enters Crowded PKU Field with a 48-Patient Safety-Only Phase 1
Changchun GeneScience starts a single-dose safety study for an undisclosed-mechanism small molecule, joining at least eight active PKU trials with no comparator arm to judge it against.
Executive Summary
- Changchun GeneScience Pharmaceutical registered a first-in-human Phase 1 trial for GenSci144 tablets, dosing 48 healthy volunteers in China to test safety and cardiac QTc effects, with no efficacy data expected before the September 1, 2026 primary completion date NCT07685210+1GenSci144 Tablets Phase I Clinical TrialNCT07685210Press ReleaseJul 6, 2026.
- The trial enters a phenylketonuria field with eight active industry trials spanning gene therapy, RNA therapy, and enzyme substitution, but GenSci144's undisclosed mechanism means it cannot yet be mapped against any of them.
- A single-dose, healthy-volunteer, safety-primary design with no comparator arm and 48 subjects can establish tolerability and pharmacokinetics; it cannot establish whether GenSci144 lowers phenylalanine levels in actual PKU patients NCT07685210GenSci144 Tablets Phase I Clinical TrialNCT07685210.
- Changchun GeneScience has completed 29 of 32 prior trials (91% completion rate) and runs 101 trials across its pipeline, indicating operational discipline even though this is its first disclosed PKU asset.
- Nothing about the competitive landscape or regulatory pathway shifts yet: no designation, no posted results, and no mechanism disclosure exist to reprice the sponsor's PKU ambitions.
The trial
Changchun GeneScience Pharmaceutical Co., Ltd. added a Phase 1 study for GenSci144 tablets to ClinicalTrials.gov on July 6, 2026, targeting 48 healthy adult volunteers in China NCT07685210GenSci144 Tablets Phase I Clinical TrialNCT07685210. The trial started June 22, 2026, and lists a primary completion date of September 1, 2026, with full study completion by December 1, 2026. The primary outcome measures are described plainly: "Adverse events and clinical safety indicators after a single dose," tracked from informed consent through Day 3 discharge, alongside change in QT/QTc interval correction measured by dynamic ECG monitoring NCT07685210GenSci144 Tablets Phase I Clinical TrialNCT07685210. This is a single-dose, first-in-human safety study, the earliest stage of clinical testing, run in healthy volunteers rather than PKU patients.
What is missing
The registry does not disclose GenSci144's molecular target or mechanism of action. A label-level mechanism lookup returned no classification for the drug, and the trial record itself lists target as "__UNKNOWN__". That gap matters because phenylketonuria therapies split cleanly by mechanism: phenylalanine hydroxylase (PAH) gene therapies, BH4 pathway modulators like sepiapterin, and SLC6A19 transport inhibitors like JNT-517 all attack the disease differently. Without knowing which pathway GenSci144 targets, the trial cannot be placed on that competitive map, and the seed's own competitive model marks first-in-class status as unresolved rather than confirmed or denied.
The competitive field
Eight active industry-sponsored trials are running in phenylketonuria globally, split 40% Phase 1, 30% Phase 2, and 30% Phase 3, with combined enrollment of 580 patients. Otsuka's JNT-517 leads with two Phase 3 trials and 360 enrolled patients targeting SLC6A19. PTC Therapeutics' sepiapterin is in Phase 3 with a primary completion date of February 2031. Sanofi's gene therapy SAR444836 carries the highest landscape risk score in the cohort at 100, flagged "Critical". None of these share a confirmed target with GenSci144, since that target is undisclosed.
What the design can and cannot show
This trial has no comparator arm; the competitive-trials tool confirms zero head-to-head or placebo-controlled comparisons tied to the study despite a placebo field appearing in search metadata. A safety-primary, single-dose, healthy-volunteer design with 48 subjects and one clinical site can establish tolerability, cardiac safety signals via QTc monitoring, and basic pharmacokinetic parameters NCT07685210GenSci144 Tablets Phase I Clinical TrialNCT07685210. It cannot establish whether GenSci144 lowers plasma phenylalanine in actual PKU patients, since none are enrolled. Any efficacy read is stages away.
Sponsor context
Changchun GeneScience Pharmaceutical Co., Ltd. has completed 29 of 32 prior trials, a 91% completion rate, and terminated three. Across its full pipeline the company runs 101 trials in various stages, including 24 currently recruiting. That record signals operational competence in trial execution, though it says nothing about the company's experience with this specific undisclosed mechanism in phenylketonuria, a program area new to its public trial record.
Protocol and regulatory status
The trial has recorded zero protocol change events since its registration, earning a "Stable" stability label, though the tool notes this is a proxy metric based on registry events rather than confirmed amendments. No regulatory designations, orphan drug status, fast track, or breakthrough therapy, appear on record for GenSci144 in phenylketonuria. No results are posted on ClinicalTrials.gov, and none are expected before the stated September 2026 completion window.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.